**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 64350

**Manuscript Type:** MINIREVIEWS

**Long-term albumin infusion in decompensated cirrhosis: A review of current literature**

Wong YJ *et al*. Albumin in decompensated cirrhosis

Yu Jun Wong, Rahul Kumar, Yu Jing Jonathan Chua, Tiing Leong Ang

**Yu Jun Wong, Rahul Kumar, Tiing Leong Ang,** Department ofGastroenterology and Hepatology, Changi General Hospital, Singapore 529889, Singapore

**Yu Jing Jonathan Chua,** Department of Internal Medicine, Yong Loo Lin School of Medicine, Singapore 117597, Singapore

**Author contributions:** Wong YJ performed the study concept and design; Wong YJ and Chua YJJ performed the systematic review of literature, drafting the manuscript; Kumar R and Ang TL performed the critical review of the manuscript.

**Supported by** Nurturing Clinician Scientist Scheme award by SingHealth Duke-NUS Medicine Academic Medicine Programme (Medicine ACP), Changi General Hospital Research Grant.

**Corresponding author: Tiing Leong Ang, FASGE, FRCP, MBBS, Attending Doctor, Chief Physician, Professor,** Department ofGastroenterology and Hepatology, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore. ang.tiing.leong@singhealth.com.sg

**Received:** February 17, 2021

**Revised:** March 22, 2021

**Accepted:** April 13, 2021

**Published online:**

**Abstract**

Decompensated cirrhosis is characterized by chronic inflammation and severe portal hypertension leading to systemic circulatory dysfunction. Albumin infusion has been widely used in decompensated cirrhosis in patients with spontaneous bacterial peritonitis, large-volume paracentesis and hepatorenal syndrome. Emerging data suggest long-term albumin infusion has both oncotic and non-oncotic properties which may improve the clinical outcomes in decompensated cirrhosis patients. We review the current literature on both the established and potential role of albumin, and specifically address the controversies of long-term albumin infusion in decompensated cirrhosis patients.

**Key Words:** Albumin; Cirrhosis; Hepatic encephalopathy; Hepatorenal syndrome; Acute-on-chronic liver failure; Spontaneous bacterial peritonitis; Large-volume paracentesis

Wong YJ, Kumar R, Chua YJJ, Ang TL. Long-term albumin infusion in decompensated cirrhosis: A review of current literature. *World J Hepatol* 2021; In press

**Core Tip:** Decompensated cirrhosis is characterized by chronic inflammation and severe portal hypertension leading to systemic circulatory dysfunction. Albumin infusion has been widely used in decompensated cirrhosis in patients with spontaneous bacterial peritonitis, large-volume paracentesis and hepatorenal syndrome. Emerging data suggest long-term albumin infusion has both oncotic and non-oncotic properties which may improve the clinical outcomes in decompensated cirrhosis patients.

**INTRODUCTION**

***Long-term albumin infusion in decompensated cirrhosis: A critical review of current literature***

**Conceptof compensated and decompensated cirrhosis**: Cirrhosis represents the common pathway of all chronic liver disease resulting in over a million deaths every year[1]. The natural history of liver cirrhosis includes an asymptomatic compensated stage and a decompensated cirrhosis stage with clinically overt complications as ascites, jaundice, variceal bleeding and hepatic encephalopathy (HE)[2]. The median survival reduces significantly from 12 to 2 years as patients progress from the compensated to decompensated cirrhosis at an annual rate of 5%-7%[2,3].

Decompensated cirrhosis is characterized by chronic inflammation and severe portal hypertension leading to systemic circulatory dysfunction[4]. As a corrective response to portal hypertension, excessive nitric oxide secretion results in both splanchnic and arterial vasodilatation, which thus impairs organ perfusion[5,6]. To ensure adequate organ perfusion, the arterial pressure is maintained by increased activity of the renin-aldosterone-angiotensin system[7]. The understanding of circulatory dysfunction in patients with decompensated cirrhosis has led to the use of albumin and vasoconstrictors to improve circulatory dysfunction and prevent kidney injury[8]. Such an approach is paramount because the presence of acute kidney injury (AKI) is associated with significantly longer hospitalization stay and higher mortality in patients with decompensated cirrhosis[9].

Human albumin has widely been used in decompensated cirrhosis patients for varying indications. While the established indications of albumin infusion as endorsed by the current societal guidance include spontaneous bacterial peritonitis (SBP), large-volume paracentesis (LVP) and hepatorenal syndrome (HRS)[10], albumin infusion is often used beyond these indications in the daily clinical practice. Although some of the recently published studies have reported the beneficial effect of regular long-term albumin infusion in patients with decompensated cirrhosis[11-13], regular long term albumin infusion is not completely innocuous. Not only is albumin more expensive than crystalloids as volume expander, serious adverse events as pulmonary oedema and even death have also been reported[14].

With this background, we aim to critically review the current literature on both the established and potential role of albumin, and specifically addressed the controversies of long-term albumin infusion in decompensated cirrhosis patients.

**WHAT IS ALBUMIN?**

Albumin is the main circulating protein in healthy adults. Structurally it is a small (66500 Dalton), negatively-charged protein that consists of 2 sub-domains[15,16]. Albumin is exclusively synthesized within the liver. It is up-regulated by hormones (insulin, cortisol and growth hormone)[17-19] and down-regulated by inflammatory mediators (tumor necrosis factor and interleukin-6)[20]. Once produced, up to 40% of albumin is released into the bloodstream. The half-life of albumin ranges from 12 to 19 d[21]. The degradation of albumin occurs mostly within the liver, kidney and muscle[22].

***Function of albumin***

Albumin has both oncotic and non-oncotic properties[15,23]. The potent oncotic property of albumin is primarily derived from the direct oncotic effect from high plasma concentration, which accounts for about two-thirds of its osmotic effect. The Gibbs-Donnan effect, where the negatively-charged albumin molecule also attracts positively charged molecules such as sodium within the bloodstream, is responsible for the remaining one-third of the osmotic effect of albumin[23].

Albumin transports hydrophobic molecules (such as bilirubin, bile acid, long-chain fatty acids) to hepatocytes for detoxification and elimination[24]. Recent evidence suggests that the effect of albumin goes beyond the oncotic functions and transport, but also include immunomodulatory and antioxidant functions as well. Albumin is shown to attenuate prostaglandin E2 mediated immune-dysfunction in patients with decompensated cirrhosis[25]. It also exerts immunomodulatory effect by down-regulating the expression of tumor necrosis factor-alpha and pro-inflammatory nuclear factor-kappa B[26]. Another property attributed to albumin is that it also functions as an antioxidant to scavenge reactive oxygen and nitrogen species in our body[27,28].

***Albumin in decompensated cirrhosis***

Hypoalbuminemia is a known predictor of poor survival in decompensated cirrhosis and serves well as a constituent of Child-Turcotte-Pugh score. What is less well appreciated is the fact that abnormalities with serum albumin in decompensated cirrhosis patients are both quantitative and qualitative[29]. The quantitative reduction of serum albumin concentration is a result of dilution from sodium and water retention, reduced synthesis from hepatocytes as well as increased trans-capillary leak, particularly amongst patients with refractory ascites[30,31]. The quality of albumin is further compromised in decompensated cirrhosis due to a higher proportion of oxidized albumin[32]. The oxidized albumin differs from native albumin because it has a lower binding capacity, impaired antioxidant properties and a shortened half-life[31]. Oxidized albumin not only correlates with the severity and complication of cirrhosis but also with short and long-term mortality[29,32]. This understanding on both the quantitative and qualitative alterations of albumin has resulted in the concept of "effective albumin concentration" in decompensated cirrhosis, which takes into account both the amount of albumin and its structural integrity[33].

**ESTABLISHED INDICATION OF ALBUMIN IN DECOMPENSATED CIRRHOSIS**

***SBP***

SBP is defined based on the presence of > 250 polymorphonuclear cells/mm3 or positive ascitic fluid cultures, in the absence of an intraabdominal source of infection or malignancy[34]. Renal impairment is reported in up to 33% patients following SBP and is associated with inpatient mortality, despite resolution of infection[34,35]. In the first randomized trial which investigated the role of intravenous albumin infusion in SBP, Sort *et al*[36] demonstrated that albumin infusion and cefotaxime significantly reduced the risk of renal impairment (33% *vs* 10%), inpatient mortality (29% *vs* 10%) and 3-month mortality (41% *vs* 22%)[36]. The benefits of albumin especially in patients at high risk of developing renal impairment (baseline serum bilirubin ≥ 4 mg/dL or creatinine ≥ 1 mg/dL) were subsequently confirmed in a meta-analysis of randomized trials[37].

Is albumin mandatory in SBP patients with low risk of renal impairment, particularly those who did not fulfil the above criteria? A meta-analysis reported a low pooled incidence of renal impairment and death (2.8% and 3.8%, respectively) among the patients with low risk of renal impairment[37]. The number needed-to-treat to prevent one case of renal impairment and death is 45 and 27, respectively. Given the limited data in low-risk SBP patients, further prospective randomized trials are required to confirm the benefit of albumin infusion in SBP patients with low risk of renal impairment.

***Post-paracentesis circulatory dysfunction***

Paracentesis-induced circulatory dysfunction (PICD) is a known complication of LVP in patients with decompensated cirrhosis. The reported incidence varies widely between 17.1% to as high as 72.7%, depending on whether albumin infusion was given during LVP[38]. PICD classically has been defined as at-least 50% or more rise in serum renin levels up to 6 d following a large volume paracentesis[39]. PICD can lead to arterial hypotension and the resultant renal impairment has been associated with readmissions and mortality[39].

Several studies have evaluated the role of albumin infusion in large volume paracentesis. Albumin infusion (given at 6-8 g/L of ascitic fluid drained) has shown to prevent PICD in paracentesis beyond 5 L[39,40]. In a meta-analysis of randomized trials, albumin infusion is associated with a lower risk of PICD (OR = 0.39, 95%CI: 0.27-0.55) and mortality (OR = 0.64, 95%CI: 0.41-0.98) following paracentesis[38]. Specifically, all the included trials removed beyond 5 L of ascitic fluid; the majority of the studies administered 6-8 g of albumin 20% *per* L of ascitic fluid removed. With this understanding, the current guidelines recommending albumin replacement in paracentesis beyond 5 L to prevent PICD[38].

***HRS***

HRS is the functional renal failure secondary to intrarenal vasoconstriction in patients with decompensated cirrhosis or acute liver failure[10]. Emerging data suggest HRS to be driven by both renal hypoperfusion from systemic circulatory dysfunction as well as increased circulating pro-inflammatory cytokines[41].

Currently, most of the evidence for albumin infusion in HRS is derived from HRS type 1 (also known as HRS-AKI). In a prospective, non-randomized study to investigate the role of albumin infusion, with and without terlipressin, in patients with HRS-AKI, Ortega *et al*[42] demonstrated that albumin infusion significantly improves HRS-AKI in addition to terlipressin alone (albumin: 77% *vs* 25%)[42]. Ever since then, albumin has become an integral part of HRS treatment with vasoactive drugs such as terlipressin, noradrenaline or octreotide[42-53]. Most studies administer 20-40 g of albumin *per* day and titrate according to fluid status to avoid fluid overload. Combination of albumin and terlipressin reverse HRS-AKI in up to 56% of patients in randomized clinical trials[43-45]. However, treatment-related adverse events leading to treatment discontinuation still occur in up to 43% of patients during the clinical trials. These complications (namely acute coronary syndromes and peripheral vascular ischemia) are mostly caused by intense systemic vasoconstriction attributable to terlipressin and can be partially mitigated by continuous terlipressin infusion (complication rates of 35% *vs* 62%), without compromising the treatment efficacy[46].

Even though albumin and terlipressin infusion achieves reversal of HRS-AKI in up to 60% of patients, it may not eventually result in reduced mortality. Several notable studies have evaluated the mortality benefit of albumin and vasoconstrictor in HRS-AKI with conflicting results[43-45,47-53]. Based on two of the recent meta-analyses, there is no conclusive survival benefit of albumin and vasoconstrictor infusion in HRS-AKI when compared to placebo[54,55].

Type-2 HRS is different from type-1 as it has a more subtle course and lower short-term mortality. Albumin and terlipressin infusion has also been shown to improve renal function in HRS type 2. However, the recurrence rate of HRS type 2 after treatment discontinuation is high and there is no clear benefit on mortality of these patients[56-58].

**THE ROLE OF ALBUMIN IN DECOMPENSTAED CIRRHOSIS: BEYOND GUIDANCE**

***Non-SBP infection***

As the circulating human albumin is less than optimal both quantitatively and qualitatively in decompensated cirrhosis. Theoretically, the benefit of albumin infusion may be expanded to non-SBP infection, especially those with renal impairment. It is also widely accepted that while renal impairment is often reversible in patients with decompensated cirrhosis with non-SBP infection, the 3-mo mortality is significantly higher compared to patients without renal impairment (55% *vs* 13%)[59]. Some notable literatures have tried to answer this quandary with help of randomised clinical trials (RCT). In a single-center RCT, Guevara *et al*[60] randomized 110 patients with non-SBP infections to receive standard antibiotics with or without albumin[60]. The dose of albumin administered was similar to SBP (1.5 g/kg on day 1 and 1 g/kg on day 3) regimen. Despite a reduction in serum creatinine, renin and aldosterone (which indicates an improvement in renal and circulatory function), the 3-mo survival rates were similar between the two groups[60]. In another RCT, Thévenot *et al*[61] randomized 191 patients with decompensated cirrhosis (Child-Pugh score > 8) with sepsis to receive albumin in addition to antibiotic. The rate of renal failure and mortality at three months were similar in both groups (albumin: 14.3% *vs* 13.5%, and, albumin: 70.2% *vs* 78.3%, respectively)[61]. However, 8.3% of patients developed pulmonary oedema following albumin infusion, and two patients died as a result of pulmonary oedema. These findings were confirmed in a recent meta-analysis of randomized trials, which showed that albumin infusion did not reduce the risk of renal impairment or death in non-SBP infection[14]. As albumin infusion did not improve renal function or survival, yet may result in adverse events such as pulmonary oedema or even death, the current guideline does not recommend albumin infusion for patients with non-SBP infection[10].

***HE***

HE is a neuropsychiatric manifestation associated with poor prognosis in decompensated cirrhosis resulting from the complex interplay between effective circulatory volume, ammonia, systemic inflammation and portosystemic shunting. As albumin is known to improve systemic circulatory dysfunction and oxidative stress-mediated tissue injury, there has been growing interest in using albumin to treat or prevent HE.

The preventive role of albumin infusion was investigated in a single center cohort study by Riggio *et al*[62] The author enrolled 23 patients following Transjugular intrahepatic portal-systemic shunt (TIPSS) to receive albumin infusion for three weeks. The risk of developing new HE was similar to a historical cohort which did not receive albumin infusion[62], suggesting that infusion of albumin may not have any role in preventing TIPSS or systemic shunting-related HE.

The role of albumin for the treatment of HE was first studied in 15 alcoholic cirrhosis patients with diuretic-induced HE. Patients were randomized to receive albumin or colloid infusion titrated accordingly to the central venous pressure[63]. Despite having a similar reduction in serum ammonia in both groups, the albumin group has a greater improvement in HE grade. Similar beneficial effects were observed in a prospective, open-labelled randomized study, Sharma *et al*[64] enrolled 120 patients with overt HE (graded based on the West Haven criteria) to receive either lactulose, with and without albumin[64]. Albumin was administered at 1.5 g/kg/d until the resolution of HE or day 10 of admission. Albumin group was more likely to achieve complete resolution of HE (albumin: 75% *vs* 53%), shorted hospitalization stays (albumin: 6.4 d *vs* 8.6 d) and lower mortality (albumin: 18% *vs* 32%). Furthermore, the albumin group had a greater decline in the serum tumor necrosis factor alfa, interleukin-6 and endotoxin level when compared to lactulose alone. However, this beneficial effect of albumin is not consistently demonstrated across studies. In a multicenter, double-blind, randomized controlled study, 56 patients with HE were randomized to receive albumin infusion (1.5 g/kg on day 1 and 1 g/kg on day 3) *vs* 0.9% saline[65]. This study remarkably did not find any significant difference in HE resolution by day 4, even though albumin infusion was associated with better transplant-free survival in patients with HE [hazard ratio (HR) 0.27, 95%CI: 0.11-0.74]. The current societal guidelines do not endorse the use of long-term albumin infusion for either the treatment or prevention of HE in patients with decompensated cirrhosis[10].

***Acute-on-chronic liver failure***

Acute-on-chronic liver failure (ACLF) is a distinct clinical entity characterized by systemic inflammation associated with multiorgan failure and high short-term mortality among decompensated cirrhosis patients[66]. As systemic inflammation is the hallmark of ACLF, the pleiotropic properties of albumin to rapidly expand the intravascular volume and ameliorate systemic inflammation makes albumin a promising treatment option in ACLF. Although clinical studies in past investigating the role of extracorporeal devices[67,68] provide the proof of concept that albumin infusion could play an effective role in the management of patients with ACLF, only a few studies have been carried out to specifically investigate the effect of albumin infusion in patients with ACLF.

In a recent multicenter randomized study (INFECIR-2 trial), Fernández *et al*[69] randomized 108 patients with decompensated cirrhosis and non-SBP infection resulting in ACLF to receive albumin or placebo in addition to antibiotic[69]. More patients in the albumin group experienced resolution of ACLF (82.3% *vs* 33.3%), even though the overall mortality were similar to patients receiving antibiotics alone[69]. Though promising, more robust data is required to support the use of albumin in ACLF.

**LONG-TERM ALBUMIN IN DECOMPENSATED CIRRHOSIS**

There have been growing interests in long-term albumin use among decompensated cirrhosis patients. We summarize all the relevant studies describing the use of long-term albumin in decompensated cirrhosis in Table 1. Wilkinson and Sherlock[70] first studied the role of long-term albumin infusion in the 1960s. They randomized 16 patients with diuretic refractory ascites to receive albumin infusion *vs* standard medical therapy (SMT)[70]. Albumin infusion was titrated based on serum oncotic pressure and maintained up to 19 mo. Apart from improving general "well-being", long-term albumin infusion did not improve overall survival or reduce the need for diuretics.

In another single center randomized study, Gentilini *et al*[71] enrolled 126 patients with refractory ascites to receive either albumin infusion or SMT[71]. Patients received weekly albumin infusion of 25 g in the first year, followed by 25 g every two weeks up to 3 years. Long-term albumin infusion reduced ascites recurrence and ascites-related readmission without improving the overall survival. Subsequently, the same group performed a follow-up study 7 years later in 2006, evaluating the long-term outcomes of long-term albumin infusion with an extension of the follow-up period to a median of 84 mo[72]. They recruited 100 patients with new-onset, clinically significant ascites and randomized them to receive either albumin or SMT. The effect of long-term albumin in ascites management was again demonstrated, with less ascites recurrence (39% *vs* 85%) in the albumin group. More importantly, long-term albumin infusion improved 5-year transplant-free survival (albumin: 62% *vs* 26%) for the first time, even though the sample size was relatively small.

The ANSWER study (the human Albumin for the TreatmeNt of aScites in patients With hEpatic cirRhosis) enrolled 431 patients of decompensated cirrhosis with medically controlled ascites and compared the clinical outcomes in patients receiving long term albumin infusion *vs* SMT[11]. In this study, long term albumin infusion (40 g twice weekly for two weeks, followed by 40 g weekly) in addition to SMT was associated with significantly lower mortality (HR 0.62, 95%CI: 0.40-0.95). The ascites control were better in albumin group with a lower risk for paracentesis (HR 0.48, 95%CI: 0.35-0.54) and refractory ascites (HR 0.43, 95%CI: 0.29-0.62). Also, long-term albumin infusion was associated with a lower risk of both SBP and non-SBP related bacterial infection, grade III and IV HE, HRS, renal dysfunction and hyponatremia. Long-term albumin infusion was well-tolerated. Finally, long-term albumin infusion was also shown to be cost-effective, primarily by a reduction in hospital admission, risk of paracentesis and HRS.

In another prospective but non-randomized study, Di Pascoli *et al*[13] enrolled 70 patients with cirrhosis and refractory ascites to receive either long-term albumin infusion *vs* SMT[13], with the primary endpoint of 24-mo survival. Subjects in the albumin group received 20 g of albumin twice weekly. The study demonstrated a significant improvement in 24-mo survival in the albumin group when compared to the SMT (58% *vs* 35% in SMT) over a mean follow up of 408 d. Furthermore, the albumin group had a lower risk of emergency hospitalizations from SBP, non-SBP infection and HE. While the liver transplantation rate was similar in both groups (11% *vs* 8% in SMT), it should be highlighted that none of the patients with refractory ascites received Transjugular intrahepatic portosystemic shunt (TIPS). More data is required to evaluate the comparative efficacy of long-term albumin and TIPS for refractory ascites.

The MACHT trial (midodrine and albumin for cirrhotic patients in the waiting list for liver transplantation) however offered a contrasting view on the survival benefit of long-term albumin in decompensated cirrhosis patients[12]. In this multicenter, randomized, double-blind, placebo-controlled trial, 196 patients on the transplant waiting list were enrolled to receive either SMT or albumin infusion (40 g every 15 d for one year) plus midodrine with cirrhosis-related complications being the primary end-point. In contrast to the ANSWER trial, the cirrhosis-related complications, ascites control and overall survival were similar between albumin and SMT group. However, 3 important features of the MACHT trial must be considered and the results interpreted in accordingly. First, a relatively higher proportion of patients in both groups received transplantation, (68% in albumin *vs* 55% in SMT group). Second, the duration of albumin therapy was relatively short (median duration of 80 d). Thirdly, the dose of albumin therapy used was also lower than that used in all the other studies. A dosage of 40 g every 15 d was used, as compared to higher dosages in all the other trials. The failure of albumin therapy group to show a better outcome may potentially be attributed to these three factors.

**IS LONG-TERM ALBUMIN READY FOR PRIME TIME?**

The ANSWER study has provided valuable insights on using long-term albumin infusion as a pathophysiological approach to prevent cirrhosis related complications and death in stable cirrhosis patients with medically-controlled ascites. Nevertheless, it is worth noting that the ANSWER study excluded more advanced-cirrhosis patient with refractory ascites and recent decompensation (variceal bleeding, bacterial infection). In patients with refractory ascites, the comparative efficacy between long-term albumin infusions *vs* TIPS, which is a one-off procedure with good efficacy, remains unanswered. Besides, only 3.2% (14/431) of patients with hepatitis C related cirrhosis received direct-acting antiviral therapy in the ANSWER study. As the treatment with direct-acting viral therapy is expected to improve the clinical outcomes in these patients[73,74], whether this specific subset of decompensated patients would benefit from long-term albumin infusion following sustained virological response remains unanswered.

The most recent published data, although in abstract form, evaluating the benefits of albumin infusion comes from the ATTIRE (Albumin to prevent infection in chronic liver failure) study which included patients with cirrhosis hospitalized for acute decompensation and hypoalbuminemia (serum albumin < 30 g/L)[75]. In this multicenter randomized trial which enrolled 778 patients to receive albumin infusion *vs* SMT, the primary endpoint was having a new infection, renal dysfunction or mortality from day 3 to 15 of treatment. The results of this study show that the risk of renal dysfunction and death were similar between albumin and SMT group and thus albumin infusion may not be beneficial in these patients. The PRECOISA (Effect of long-term administration of albumin in subjects with decompensated cirrhosis and ascites) study which aims to investigate the impact of long-term albumin on the 1-year mortality and ACLF, is currently ongoing (NCT03451282). The results of PRECOISA will hopefully provide robust evidence for the use of long-term albumin infusion in decompensated cirrhosis patients.

**CONCLUSION**

Decompensated cirrhosis is characterized by systemic circulatory dysfunction from portal hypertension and systemic inflammation. In decompensated cirrhosis, albumin dysfunction both in terms of quantity and quality. The established therapeutic role of albumin infusion in decompensated cirrhosis includes SBP, HRS and in patients undergoing LVP. Although long-term albumin seemed promising to prevent ascites-related complications in decompensated cirrhosis, the existing studies were heterogeneous in terms of their study population, follow-up duration, and the dose of albumin infusion, thus making the interpretation on the survival benefit particularly challenging. The positive results of long-term albumin infusion will likely increase the global demand for intravenous albumin, particularly among decompensated cirrhosis patients. Meanwhile, the cell-free concentrated ascites reinfusion therapy (CART) may be a novel alternative to intravenous albumin infusion in patients with ascites[76], however more data is required to evaluate the efficacy and safety of CART, particularly among cirrhosis patients with refectory ascites.

Future upcoming studies evaluating the role of long-term albumin infusion to ameliorate systemic inflammation and cirrhosis-related complications are expected in the next few years. Till then, the use of albumin beyond the established indication should be individualized. Future studies should focus on refining the dosages, schedule of long-term albumin infusion and on the specific population groups which would benefit the most.

**REFERENCES**

1 **GBD 2017 Cirrhosis Collaborators.** The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol* 2020; **5**: 245-266 [PMID: 31981519 DOI: 10.1016/S2468-1253(19)30349-8]

2 **D'Amico G**, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol* 2006; **44**: 217-231 [PMID: 16298014 DOI: 10.1016/j.jhep.2005.10.013]

3 **Fleming KM**, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. *Aliment Pharmacol Ther* 2010; **32**: 1343-1350 [PMID: 21050236 DOI: 10.1111/j.1365-2036.2010.04473.x]

4 **Arroyo V**, Angeli P, Moreau R, Jalan R, Clària J, Trebicka J, Fernández J, Gustot T, Caraceni P, Bernardi M; investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif). The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. *J Hepatol* 2021; **74**: 670-685 [PMID: 33301825 DOI: 10.1016/j.jhep.2020.11.048]

5 **Battista S**, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. *J Hepatol* 1997; **26**: 75-80 [PMID: 9148026 DOI: 10.1016/s0168-8278(97)80012-8]

6 **Møller S**, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. *Liver Int* 2018; **38**: 570-580 [PMID: 28921803 DOI: 10.1111/liv.13589]

7 **Schrier RW**, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. *Hepatology* 1988; **8**: 1151-1157 [PMID: 2971015 DOI: 10.1002/hep.1840080532]

8 **Bernardi M**, Angeli P, Claria J, Moreau R, Gines P, Jalan R, Caraceni P, Fernandez J, Gerbes AL, O'Brien AJ, Trebicka J, Thevenot T, Arroyo V. Albumin in decompensated cirrhosis: new concepts and perspectives. *Gut* 2020; **69**: 1127-1138 [PMID: 32102926 DOI: 10.1136/gutjnl-2019-318843]

9 **Moreau R**, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013; **144**: 1426-1437, 1437.e1-1437.e9 [PMID: 23474284 DOI: 10.1053/j.gastro.2013.02.042]

10 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol* 2018; **69**: 406-460 [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024]

11 **Caraceni P**, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S, Svegliati-Baroni G, Fagiuoli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M; ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. *Lancet* 2018; **391**: 2417-2429 [PMID: 29861076 DOI: 10.1016/S0140-6736(18)30840-7]

12 **Solà E**, Solé C, Simón-Talero M, Martín-Llahí M, Castellote J, Garcia-Martínez R, Moreira R, Torrens M, Márquez F, Fabrellas N, de Prada G, Huelin P, Lopez Benaiges E, Ventura M, Manríquez M, Nazar A, Ariza X, Suñé P, Graupera I, Pose E, Colmenero J, Pavesi M, Guevara M, Navasa M, Xiol X, Córdoba J, Vargas V, Ginès P. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. *J Hepatol* 2018; **69**: 1250-1259 [PMID: 30138685 DOI: 10.1016/j.jhep.2018.08.006]

13 **Di Pascoli M**, Fasolato S, Piano S, Bolognesi M, Angeli P. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. *Liver Int* 2019; **39**: 98-105 [PMID: 30230204 DOI: 10.1111/liv.13968]

14 **Wong YJ**, Qiu TY, Tam YC, Mohan BP, Gallegos-Orozco JF, Adler DG. Efficacy and Safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: A systematic review and meta-analysis. *Dig Liver Dis* 2020; **52**: 1137-1142 [PMID: 32586766 DOI: 10.1016/j.dld.2020.05.047]

15 **Peters JT.** All about Albumin: Biochemistry, Genetics and Medical Applications. San Diego and London: Academic Press, 1996: 432

16 **He XM**, Carter DC. Atomic structure and chemistry of human serum albumin. *Nature* 1992; **358**: 209-215 [PMID: 1630489 DOI: 10.1038/358209a0]

17 **Peavy DE**, Taylor JM, Jefferson LS. Time course of changes in albumin synthesis and mRNA in diabetic and insulin-treated diabetic rats. *Am J Physiol* 1985; **248**: E656-E663 [PMID: 3890555 DOI: 10.1152/ajpendo.1985.248.6.E656]

18 **Moshage HJ**, de Haard HJ, Princen HM, Yap SH. The influence of glucocorticoid on albumin synthesis and its messenger RNA in rat *in vivo* and in hepatocyte suspension culture. *Biochim Biophys Acta* 1985; **824**: 27-33 [PMID: 3967027 DOI: 10.1016/0167-4781(85)90025-9]

19 **Kernoff LM**, Pimstone BL, Solomon J, Brock JF. The effect of hypophysectomy and growth hormone replacement on albumin synthesis and catabolism in the rat. *Biochem J* 1971; **124**: 529-535 [PMID: 5135239 DOI: 10.1042/bj1240529]

20 **Castell JV**, Gómez-Lechón MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. *FEBS Lett* 1989; **242**: 237-239 [PMID: 2464504 DOI: 10.1016/0014-5793(89)80476-4]

21 **Prinsen BH**, de Sain-van der Velden MG. Albumin turnover: experimental approach and its application in health and renal diseases. *Clin Chim Acta* 2004; **347**: 1-14 [PMID: 15313137 DOI: 10.1016/j.cccn.2004.04.005]

22 **Yedgar S**, Carew TE, Pittman RC, Beltz WF, Steinberg D. Tissue sites of catabolism of albumin in rabbits. *Am J Physiol* 1983; **244**: E101-E107 [PMID: 6849378 DOI: 10.1152/ajpendo.1983.244.1.E101]

23 **Nguyen MK**, Ornekian V, Kao L, Butch AW, Kurtz I. Defining the role of albumin infusion in cirrhosis-associated hyponatremia. *Am J Physiol Gastrointest Liver Physiol* 2014; **307**: G229-G232 [PMID: 24833711 DOI: 10.1152/ajpgi.00424.2013]

24 **Petersen CE**, Ha CE, Harohalli K, Feix JB, Bhagavan NV. A dynamic model for bilirubin binding to human serum albumin. *J Biol Chem* 2000; **275**: 20985-20995 [PMID: 10764755 DOI: 10.1074/jbc.M001038200]

25 **O'Brien AJ**, Fullerton JN, Massey KA, Auld G, Sewell G, James S, Newson J, Karra E, Winstanley A, Alazawi W, Garcia-Martinez R, Cordoba J, Nicolaou A, Gilroy DW. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. *Nat Med* 2014; **20**: 518-523 [PMID: 24728410 DOI: 10.1038/nm.3516]

26 **Zhang WJ**, Frei B. Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. *Cardiovasc Res* 2002; **55**: 820-829 [PMID: 12176131 DOI: 10.1016/s0008-6363(02)00492-3]

27 **Garcia-Martinez R**, Andreola F, Mehta G, Poulton K, Oria M, Jover M, Soeda J, Macnaughtan J, De Chiara F, Habtesion A, Mookerjee RP, Davies N, Jalan R. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. *J Hepatol* 2015; **62**: 799-806 [PMID: 25450713 DOI: 10.1016/j.jhep.2014.10.031]

28 **Carballal S**, Radi R, Kirk MC, Barnes S, Freeman BA, Alvarez B. Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. *Biochemistry* 2003; **42**: 9906-9914 [PMID: 12924939 DOI: 10.1021/bi027434m]

29 **Oettl K**, Birner-Gruenberger R, Spindelboeck W, Stueger HP, Dorn L, Stadlbauer V, Putz-Bankuti C, Krisper P, Graziadei I, Vogel W, Lackner C, Stauber RE. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. *J Hepatol* 2013; **59**: 978-983 [PMID: 23811308 DOI: 10.1016/j.jhep.2013.06.013]

30 **Henriksen JH**, Siemssen O, Krintel JJ, Malchow-Møller A, Bendtsen F, Ring-Larsen H. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. *J Hepatol* 2001; **34**: 53-60 [PMID: 11211908 DOI: 10.1016/s0168-8278(00)00009-x]

31 **Jalan R**, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, Muravsky V, Williams R, Matthes G, Davies NA. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. *Hepatology* 2009; **50**: 555-564 [PMID: 19642174 DOI: 10.1002/hep.22913]

32 **Domenicali M**, Baldassarre M, Giannone FA, Naldi M, Mastroroberto M, Biselli M, Laggetta M, Patrono D, Bertucci C, Bernardi M, Caraceni P. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. *Hepatology* 2014; **60**: 1851-1860 [PMID: 25048618 DOI: 10.1002/hep.27322]

33 **Jalan R**, Bernardi M. Effective albumin concentration and cirrhosis mortality: from concept to reality. *J Hepatol* 2013; **59**: 918-920 [PMID: 23954671 DOI: 10.1016/j.jhep.2013.08.001]

34 **Wong YJ**, Kalki RC, Lin KW, Kumar R, Tan J, Teo EK, Li JW, Ang TL. Short- and long-term predictors of spontaneous bacterial peritonitis in Singapore. *Singapore Med J* 2020; **61**: 419-425 [PMID: 31363784 DOI: 10.11622/smedj.2019085]

35 **Follo A**, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodés J. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. *Hepatology* 1994; **20**: 1495-1501 [PMID: 7982650 DOI: 10.1002/hep.1840200619]

36 **Sort P**, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *N Engl J Med* 1999; **341**: 403-409 [PMID: 10432325 DOI: 10.1056/NEJM199908053410603]

37 **Salerno F**, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. *Clin Gastroenterol Hepatol* 2013; **11**: 123-30.e1 [PMID: 23178229 DOI: 10.1016/j.cgh.2012.11.007]

38 **Bernardi M**, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. *Hepatology* 2012; **55**: 1172-1181 [PMID: 22095893 DOI: 10.1002/hep.24786]

39 **Ginès A**, Fernández-Esparrach G, Monescillo A, Vila C, Domènech E, Abecasis R, Angeli P, Ruiz-Del-Arbol L, Planas R, Solà R, Ginès P, Terg R, Inglada L, Vaqué P, Salerno F, Vargas V, Clemente G, Quer JC, Jiménez W, Arroyo V, Rodés J. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. *Gastroenterology* 1996; **111**: 1002-1010 [PMID: 8831595 DOI: 10.1016/s0016-5085(96)70068-9]

40 **Sola-Vera J**, Miñana J, Ricart E, Planella M, González B, Torras X, Rodríguez J, Such J, Pascual S, Soriano G, Pérez-Mateo M, Guarner C. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. *Hepatology* 2003; **37**: 1147-1153 [PMID: 12717396 DOI: 10.1053/jhep.2003.50169]

41 **Stadlbauer V**, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, Jalan R. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. *Gastroenterology* 2008; **134**: 111-119 [PMID: 18166350 DOI: 10.1053/j.gastro.2007.10.055]

42 **Ortega R**, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. *Hepatology* 2002; **36**: 941-948 [PMID: 12297842 DOI: 10.1053/jhep.2002.35819]

43 **Sanyal AJ**, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. *Gastroenterology* 2008; **134**: 1360-1368 [PMID: 18471513 DOI: 10.1053/j.gastro.2008.02.014]

44 **Boyer TD**, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC; REVERSE Study Investigators. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. *Gastroenterology* 2016; **150**: 1579-1589.e2 [PMID: 26896734 DOI: 10.1053/j.gastro.2016.02.026]

45 **Cavallin M**, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin *vs* midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. *Hepatology* 2015; **62**: 567-574 [PMID: 25644760 DOI: 10.1002/hep.27709]

46 **Cavallin M**, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, Gola E, Morando F, Stanco M, Rosi S, Sticca A, Cillo U, Angeli P. Terlipressin given by continuous intravenous infusion *vs* intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. *Hepatology* 2016; **63**: 983-992 [PMID: 26659927 DOI: 10.1002/hep.28396]

47 **Neri S**, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. *Dig Dis Sci* 2008; **53**: 830-835 [PMID: 17939047 DOI: 10.1007/s10620-007-9919-9]

48 **Martín-Llahí M**, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators. Terlipressin and albumin *vs* albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. *Gastroenterology* 2008; **134**: 1352-1359 [PMID: 18471512 DOI: 10.1053/j.gastro.2008.02.024]

49 **Alessandria C**, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A. Noradrenalin *vs* terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. *J Hepatol* 2007; **47**: 499-505 [PMID: 17560680 DOI: 10.1016/j.jhep.2007.04.010]

50 **Arora V**, Maiwall R, Rajan V, Jindal A, Muralikrishna Shasthry S, Kumar G, Jain P, Sarin SK. Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure. *Hepatology* 2020; **71**: 600-610 [PMID: 30076614 DOI: 10.1002/hep.30208]

51 **Goyal O**, Sidhu SS, Sehgal N, Puri S. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial. *J Assoc Physicians India* 2016; **64**: 30-35 [PMID: 27762512]

52 **Saif RU**, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline *vs* terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. *Indian J Gastroenterol* 2018; **37**: 424-429 [PMID: 30178092 DOI: 10.1007/s12664-018-0876-3]

53 **Israelsen M**, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL. Terlipressin *vs* other vasoactive drugs for hepatorenal syndrome. *Cochrane Database Syst Rev* 2017; **9**: CD011532 [PMID: 28953318 DOI: 10.1002/14651858.CD011532.pub2]

54 **Gifford FJ**, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. *Aliment Pharmacol Ther* 2017; **45**: 593-603 [PMID: 28052382 DOI: 10.1111/apt.13912]

55 **Best LM**, Freeman SC, Sutton AJ, Cooper NJ, Tng EL, Csenar M, Hawkins N, Pavlov CS, Davidson BR, Thorburn D, Cowlin M, Milne EJ, Tsochatzis E, Gurusamy KS. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. *Cochrane Database Syst Rev* 2019; **9**: CD013103 [PMID: 31513287 DOI: 10.1002/14651858.CD013103.pub2]

56 **Ghosh S**, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V. Noradrenaline *vs* terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. *Liver Int* 2013; **33**: 1187-1193 [PMID: 23601499 DOI: 10.1111/liv.12179]

57 **Nguyen-Tat M**, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. *United European Gastroenterol J* 2019; **7**: 529-537 [PMID: 31065370 DOI: 10.1177/2050640619825719]

58 **Alessandria C**, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. *Eur J Gastroenterol Hepatol* 2002; **14**: 1363-1368 [PMID: 12468959 DOI: 10.1097/00042737-200212000-00013]

59 **Terra C**, Guevara M, Torre A, Gilabert R, Fernández J, Martín-Llahí M, Baccaro ME, Navasa M, Bru C, Arroyo V, Rodés J, Ginès P. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. *Gastroenterology* 2005; **129**: 1944-1953 [PMID: 16344063 DOI: 10.1053/j.gastro.2005.09.024]

60 **Guevara M**, Terra C, Nazar A, Solà E, Fernández J, Pavesi M, Arroyo V, Ginès P. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. *J Hepatol* 2012; **57**: 759-765 [PMID: 22732511 DOI: 10.1016/j.jhep.2012.06.013]

61 **Thévenot T**, Bureau C, Oberti F, Anty R, Louvet A, Plessier A, Rudler M, Heurgué-Berlot A, Rosa I, Talbodec N, Dao T, Ozenne V, Carbonell N, Causse X, Goria O, Minello A, De Ledinghen V, Amathieu R, Barraud H, Nguyen-Khac E, Becker C, Paupard T, Botta-Fridlung D, Abdelli N, Guillemot F, Monnet E, Di Martino V. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. *J Hepatol* 2015; **62**: 822-830 [PMID: 25463545 DOI: 10.1016/j.jhep.2014.11.017]

62 **Riggio O**, Nardelli S, Pasquale C, Pentassuglio I, Gioia S, Onori E, Frieri C, Salvatori FM, Merli M. No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. *Metab Brain Dis* 2016; **31**: 1275-1281 [PMID: 26290375 DOI: 10.1007/s11011-015-9713-x]

63 **Jalan R**, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. *Clin Sci (Lond)* 2004; **106**: 467-474 [PMID: 14678008 DOI: 10.1042/CS20030357]

64 **Sharma BC**, Singh J, Srivastava S, Sangam A, Mantri AK, Trehanpati N, Sarin SK. Randomized controlled trial comparing lactulose plus albumin *vs* lactulose alone for treatment of hepatic encephalopathy. *J Gastroenterol Hepatol* 2017; **32**: 1234-1239 [PMID: 27885712 DOI: 10.1111/jgh.13666]

65 **Simón-Talero M**, García-Martínez R, Torrens M, Augustin S, Gómez S, Pereira G, Guevara M, Ginés P, Soriano G, Román E, Sánchez-Delgado J, Ferrer R, Nieto JC, Sunyé P, Fuentes I, Esteban R, Córdoba J. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. *J Hepatol* 2013; **59**: 1184-1192 [PMID: 23872605 DOI: 10.1016/j.jhep.2013.07.020]

66 **Kumar R**, Mehta G, Jalan R. Acute-on-chronic liver failure. *Clin Med (Lond)* 2020; **20**: 501-504 [PMID: 32934045 DOI: 10.7861/clinmed.2020-0631]

67 **Kribben A**, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, Sarrazin C, Hoste E, Van Vlierberghe H, Escorsell A, Hafer C, Schreiner O, Galle PR, Mancini E, Caraceni P, Karvellas CJ, Salmhofer H, Knotek M, Ginès P, Kozik-Jaromin J, Rifai K; HELIOS Study Group. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. *Gastroenterology* 2012; **142**: 782-789.e3 [PMID: 22248661 DOI: 10.1053/j.gastro.2011.12.056]

68 **Bañares R**, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Saliba F, Sauerbruch T, Klammt S, Ockenga J, Pares A, Wendon J, Brünnler T, Kramer L, Mathurin P, de la Mata M, Gasbarrini A, Müllhaupt B, Wilmer A, Laleman W, Eefsen M, Sen S, Zipprich A, Tenorio T, Pavesi M, Schmidt HH, Mitzner S, Williams R, Arroyo V; RELIEF study group. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. *Hepatology* 2013; **57**: 1153-1162 [PMID: 23213075 DOI: 10.1002/hep.26185]

69 **Fernández J**, Angeli P, Trebicka J, Merli M, Gustot T, Alessandria C, Aagaard NK, de Gottardi A, Welzel TM, Gerbes A, Soriano G, Vargas V, Albillos A, Salerno F, Durand F, Bañares R, Stauber R, Prado V, Arteaga M, Hernández-Tejero M, Aziz F, Morando F, Jansen C, Lattanzi B, Moreno C, Campion D, Gronbaek H, Garcia R, Sánchez C, García E, Amorós A, Pavesi M, Clària J, Moreau R, Arroyo V. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. *Clin Gastroenterol Hepatol* 2020; **18**: 963-973.e14 [PMID: 31394283 DOI: 10.1016/j.cgh.2019.07.055]

70 **Wilkinson P**, Sherlock S. The effect of repeated albumin infusions in patients with cirrhosis. *Lancet* 1962; **2**: 1125-1129 [PMID: 14000766 DOI: 10.1016/s0140-6736(62)90895-4]

71 **Gentilini P**, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. *J Hepatol* 1999; **30**: 639-645 [PMID: 10207805 DOI: 10.1016/s0168-8278(99)80194-9]

72 **Romanelli RG**, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, Boddi V, Tarquini R, Pantaleo P, Gentilini P, Laffi G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. *World J Gastroenterol* 2006; **12**: 1403-1407 [PMID: 16552809 DOI: 10.3748/wjg.v12.i9.1403]

73 **Lens S**, Baiges A, Alvarado-Tapias E, LLop E, Martinez J, Fortea JI, Ibáñez-Samaniego L, Mariño Z, Rodríguez-Tajes S, Gallego A, Bañares R, Puente Á, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, García-Pagán JC, Forns X. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. *J Hepatol* 2020; **73**: 1415-1424 [PMID: 32535060 DOI: 10.1016/j.jhep.2020.05.050]

74 **Wong YJ**, Thurairajah PH, Kumar R, Tan J, Fock KM, Law NM, Li W, Kwek A, Tan YB, Koh J, Lee ZC, Kumar LS, Teo EK, Ang TL. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. *J Gastroenterol Hepatol* 2020 [PMID: 33217040 DOI: 10.1111/jgh.15324]

75 **China L**, Skene SS, Bennett K, Shabir Z, Hamilton R, Bevan S, Chandler T, Maini AA, Becares N, Gilroy D, Forrest EH, O'Brien A. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial. *BMJ Open* 2018; **8**: e023754 [PMID: 30344180 DOI: 10.1136/bmjopen-2018-023754]

76 **Hanafusa N**, Isoai A, Ishihara T, Inoue T, Ishitani K, Utsugisawa T, Yamaka T, Ito T, Sugiyama H, Arakawa A, Yamada Y, Itano Y, Onodera H, Kobayashi R, Torii N, Numata T, Kashiwabara T, Matsuno Y, Kato M. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. *PLoS One* 2017; **12**: e0177303 [PMID: 28510606 DOI: 10.1371/journal.pone.0177303]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that there is no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 17, 2021

**First decision:** March 16, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Singapore

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Savarino V, Tamori A **S-Editor:** Fan JR **L-Editor: P-Editor:**

**Table 1 Characteristics of studies on long-term albumin infusion in decompensated cirrhosis patients**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **No** | **Ref.** | **Country** | **Study design** | **Follow-up duration1** | **Study population** | **Exclusion criteria** | **Duration of albumin infusion (d)** | **Sample size** | **Child-Pugh Score (A/B/C)** | **MELD score (albumin *vs* SMT)1** | **Intervention** | **Control** |
| 1 | Wilkinson and Sherlock[70], 1962 | England | Single centre, non-randomized | 22 mo | Cirrhosis patients with ascites despite 6 wk of dietary and diuretic therapy | HCC | 616 | 16 | NA | NA | Albumin 25-100 g until serum colloid oncotic pressure 38-40 cm of water | SMT |
| 2 | Gentilini *et al*[71], 1999 | Italy | Single centre, randomised controlled trial | 3 yr | Adult cirrhosis patients with ascites after 1 wk of bed rest and low sodium diet | Renal or cardiac failure, HCC or other malignancies, HE (grades 2-4), infections, gastrointestinal bleeding or DIVC | 1095 | 126 | 0/67/59 | NA | Albumin 12.5 g/d | SMT |
| 3 | Romanelli *et al*[72], 2006 | Italy | Single centre, randomised controlled trial | 84 mo (2-120) | Adult cirrhosis patients with ascites | Active alcohol abuse; previous ascites (grades 2 and 3) or HE; cardiac, respiratory or renal impairment; diabetes; refractory ascites; HCC or other malignancies; gastrointestinal bleeding; infections or DIVC | 1440 | 100 | 0/46/54 | NA | Albumin 25 g weekly in the first year, 25 g every two weeks thereafter | SMT |
| 4 | Caraceni *et al*[11], 2018 | Italy | Multicentre, randomised controlled trial | 18 mo | Adult cirrhosis patients with medically controlled uncomplicated ascites | Refractory ascites, recent decompensation, TIPS, HCC, liver transplantation, ongoing alcohol abuse, extrahepatic organ failure and albumin use for the treatment of ascites within one month | 540 | 431 | 64/282/85 | 12 (10–15), 13 (10–16) | Albumin 40 g twice weekly for 2 wk, and 40 g weekly up to 18 mo | SMT |
| 5 | Sola-Vera *et al*[40], 2003 | Spain | Multicentre, randomised controlled trial | 1 yr | Cirrhotic patients with ascites on the liver transplantation waiting list | Arterial hypertension; treatment with psychotropic drugs or antibiotic; TIPS; cardiac or respiratory failure; previous or currently listed for liver transplant; HIV or HCV infection, contraindications to midodrine | 365 | 196 | NIL | 16 ± 6.2, 17 ± 6.0, | Midodrine 15-30 mg/d and Albumin 40 g/15 d for 1 yr | SMT |
| 6 | Di Pascoli *et al*[13], 2019 | Italy | Non-randomised, prospective study | Mean 408 +/- 394 d | Adult cirrhosis patients with refractory ascites | HCC beyond Milan criteria or severe extrahepatic diseases | 720 | 70 | CTP 9.3 ± 1.7; 9.5 ± 1.6 | 15.2 ± 5.4, 14.9 ± 5 | Human albumin 20 grams twice *per* week | SMT, LVP when indicated |
| 7 | China *et al*[75], 2018 | United Kingdom | Multicentre randomised controlled trial | 6 mo | Adult cirrhosis patients hospitalised with acute decompensation and hypoalbuminemia (serum albumin < 30 g/L) | Advanced HCC; heart failure | 14 | 828 | NA | NA | Albumin 20-80 g/d until serum albumin ≥ 35 g/L | SMT |

1Presented in mean (± SD) or median (interquartile range). SMT: Standard medical therapy, HCC: Hepatocellular carcinoma; HE: Hepatic encephalopathy; DIVC: Disseminated intravascular coagulopathy; TIPS: Transjugular intrahepatic portosystemic shunt; LVP: Large-volume paracentesis; NA: Not available; NIL: Nanoimprint lithography; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; CTP: Cytoplasmic transduction peptide.